UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000046246 |
|---|---|
| Receipt number | R000052775 |
| Scientific Title | Investigation for the prevalence of anti-SARS-CoV-2 antibody. |
| Date of disclosure of the study information | 2021/12/04 |
| Last modified on | 2023/01/11 13:08:53 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Investigation for the prevalence of anti-SARS-CoV-2 antibody.
Acronym
Investigation for the prevalence of anti-SARS-CoV-2 antibody.
Scientific Title
Investigation for the prevalence of anti-SARS-CoV-2 antibody.
Scientific Title:Acronym
Investigation for the prevalence of anti-SARS-CoV-2 antibody.
Region
| Japan |
Condition
Condition
COVID-19
Classification by specialty
| Infectious disease |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the influence of post-vaccination reactions and the use of antipyretic medications on the antibody titer after the third dose of BNT162b2 vaccination.
Basic objectives2
Others
Basic objectives -Others
Investigation for vaccine effectiveness
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The influence of post-vaccination reactions and use of antipyretic medications on the anti-SARS-CoV-2 spike antibody titer
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Employees of Fukuoka City Hospital who have undergone antibody testing
Key exclusion criteria
None
Target sample size
400
Research contact person
Name of lead principal investigator
| 1st name | Naoki |
| Middle name | |
| Last name | Tani |
Organization
Kyushu University Graduate School of Medical Sciences
Division name
Medicine and Biosystemic Science
Zip code
812-8582
Address
3-1-1, Maidashi, Higashi-ward, Fukuoka-shi, Fukuoka 812-8582, Japan
TEL
+81-92-642-5229
nao_taniyan@icloud.com
Public contact
Name of contact person
| 1st name | Naoki |
| Middle name | |
| Last name | Tani |
Organization
Kyushu University Graduate School of Medical Sciences
Division name
Medicine and Biosystemic Science
Zip code
812-8582
Address
Fukuoka Japan, 3-1-1, Maidashi, Higashi-ku Fukuoka-shi, Fukuoka
TEL
+81-92-642-5229
Homepage URL
nao_taniyan@icloud.com
Sponsor or person
Institute
Fukuoka City Hospital
Institute
Department
Personal name
Funding Source
Organization
Self funding
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Fukuoka City Hospital
Address
13-1, Yoshizukahonmachi, Hakata-ward, Fukuoka-city, Fukuoka 812-0046 JAPAN
Tel
+81-92-801-1011
rinshou@adm.fukuoka-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 12 | Month | 04 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofac493/6712593
Number of participants that the trial has enrolled
281
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Main results already published
Date of protocol fixation
| 2021 | Year | 12 | Month | 01 | Day |
Date of IRB
| 2021 | Year | 11 | Month | 22 | Day |
Anticipated trial start date
| 2021 | Year | 12 | Month | 03 | Day |
Last follow-up date
| 2022 | Year | 10 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Investigation for the factors associated with the anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccination
Management information
Registered date
| 2021 | Year | 12 | Month | 01 | Day |
Last modified on
| 2023 | Year | 01 | Month | 11 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052775
